Vanta Bioscience P/E Ratio
Vanta Bioscience (VANTABIO) P/E ratio is not applicable — EPS (TTM) ₹-7.56. See Healthcare peers with valid P/E ratios below.
P/E Ratio Status
N/A
Loss Making
Company is currently reporting losses
P/E Ratio Not Applicable
Company reported a loss in the most recent quarter. P/E ratio is not meaningful for loss-making periods.
Current EPS: ₹-7.56
Recent Quarterly Performance
| Quarter | EPS (₹) | Net Profit (₹ Cr) | Status |
|---|---|---|---|
| Mar 2022 | 0.11 | 0 | Profit |
| Dec 2022 | -4.06 | -3 | Loss |
Healthcare Peers with Valid P/E Ratios — VANTABIO Comparison
Healthcare sector average P/E 48.95, median 27.18 — VANTABIO excluded (negative EPS).
Sector Average PE
48.95
Sector Median PE
27.18
Lowest PE
1.17
Profitable Companies
140
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Welcure Drugs & Pharmace… | WELCURE | 1.17 | ₹43 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Ind Swift Laboratories | INDSWFTLAB | 4.93 | ₹1,136 | Low |
| Amwill Health Care | AMWILL | 5.67 | ₹64 | Low |
| Medicamen Organics | MEDIORG | 6.4 | ₹27 | Low |
| Zenith Drugs | ZENITHDRUG | 6.83 | ₹69 | Low |
| Unichem Laboratories | UNICHEMLAB | 7.99 | ₹2,364 | Low |
| Galaxy Medicare | GML | 8.78 | ₹31 | Low |
| Brooks Laboratories | BROOKS | 9.86 | ₹211 | Low |
| Accretion Pharmaceuticals | ACCPL | 10.92 | ₹78 | Low |
Related Analysis
- For live price, revenue and the complete fundamental profile, see VANTABIO share price.
- Analyse Vanta Bioscience ownership structure to track promoter, FII and institutional holdings.
- View VANTABIO annual price range for the annual high/low range and current price position.